Vivus Will Cut Population In Qnexa Resubmission
The biotech announces it will resubmit its obesity drug by the end of October, two months ahead of schedule, after a meeting with FDA.
The biotech announces it will resubmit its obesity drug by the end of October, two months ahead of schedule, after a meeting with FDA.